{
    "nct_id": "NCT03424603",
    "official_title": "A Phase 1 Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies",
    "inclusion_criteria": "1. Confirmation of diagnosis\n2. Relapsed or relapsed/refractory disease\n3. Age ≥ 18 years\n4. ECOG performance status (0-2)\n5. Life expectancy > 3 months\n6. Adequate bone marrow and renal functions\n7. QTcF <500 msec\n8. Ability to comply with treatment, PK and test schedules\n9. NHL only- at least one measurable lesion\n\nKey\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "1. Active plasma cell leukemia and/or leukemic manifestations of lymphoma\n2. Known amyloidosis (MM patients)\n3. Chronic lymphocytic leukemia and Richter's transformation, and prolymphocytic leukemia (NHL subjects)\n4. T-cell malignancy\n5. Sensory or motor neuropathy ≥ grade 2\n6. Chronic or ongoing active infectious disease requiring systemic treatment such as, but not limited to, chronic renal infection, chronic chest infection with bronchiectasis, tuberculosis and active hepatitis C\n7. Ongoing immunosuppressive therapy, including systemic corticosteroids. Note: Subjects may be using topical or inhaled corticosteroids.\n8. Clinically significant cardiac disease\n9. Significant concurrent, uncontrolled medical condition\n10. History or clinical signs of meningeal or active CNS involvement\n11. Known severe chronic obstructive pulmonary disease or asthma\n12. History of significant cerebrovascular disease\n13. Known Human Immunodeficiency Virus seropositivity\n14. Positive serology for hepatitis B defined by a positive test for HBsAg\n15. Concurrent participation in another therapeutic treatment trial\n16. High screening liver function tests\n17. Prior treatment with CD74 targeting therapy",
    "miscellaneous_criteria": "Key"
}